专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20110201039A1 IMPROVED VIRAL PROTEIN QUANTIFICATION PROCESS AND VACCINE QUALITY CONTROL THEREWITH 有权
标题翻译：改进的病毒蛋白质定量过程和疫苗质量控制
公开(公告)号：US20110201039A1
公开(公告)日：2011-08-18
申请号：US12746649
申请日：2008-12-05
申请人： John R. Barr , Tracie L. Williams , Leah G. Luna , Zhu Guo , Rubin Donis , James L. Pirkle
发明人： John R. Barr , Tracie L. Williams , Leah G. Luna , Zhu Guo , Rubin Donis , James L. Pirkle
IPC分类号： C12Q1/37
CPC分类号： G01N30/7233 , G01N2030/045 , G01N2030/8831 , G01N2030/8868
摘要： A process of quantifying proteins in a complex mixture is provided. The invention has utility in quantifying proteins in a complex preparation of uni- or multivalent commercial or research vaccine preparations.
摘要翻译：提供了在复杂混合物中定量蛋白质的过程。本发明可用于定量单价或多价商业或研究疫苗制剂的复杂制剂中的蛋白质。

2. 发明申请

US20110171316A1 EXPRESSION AND ASSEMBLY OF HUMAN GROUP C ROTAVIRUS-LIKE PARTICLES AND USES THEREOF 有权
标题翻译：人类C类罗氏样颗粒的表达和组装及其用途
公开(公告)号：US20110171316A1
公开(公告)日：2011-07-14
申请号：US12995024
申请日：2009-05-29
申请人： Baoming Jiang
发明人： Baoming Jiang
IPC分类号： A61K39/15 , C07K14/14 , A61K9/14 , C12P21/00 , A61P37/04 , A61P31/14 , C12Q1/02
CPC分类号： C07K14/005 , A61K39/12 , A61K2039/5258 , C12N2710/14143 , C12N2720/12322 , C12N2720/12323 , C12N2720/12334
摘要： Group C rotaviruses are a cause of acute gastroenteritis in children and adults that is distinct from group A RV. However, human group C rotaviruses cannot be grown in culture, resulting in a lack of tools for detection and treatment of GrpC RV disease. Consequently, the burden of GpC RV disease has not been clearly established. Isolated recombinant human rotavirus group C virus-like particles are provided according to embodiments of the present invention along with methods of their production and use in, inter alia, detection of Grp C RV infection, diagnostic assays and immunogenic compositions.
摘要翻译： C组轮状病毒是与A组RV不同的儿童和成人的急性胃肠炎的原因。然而，人类C型轮状病毒不能在培养物中生长，导致缺乏用于检测和治疗GrpC RV疾病的工具。因此，GpC RV疾病的负担尚未明确。根据本发明的实施方案提供分离的重组人轮状病毒组C病毒样颗粒以及其生产和用于特别是检测Grp C RV感染，诊断测定和免疫原性组合物的方法。

3. 发明申请

US20110268749A1 TREATMENT OF CANCER VIA TARGETING OF IL-13 RECEPTOR-ALPHA2 审中-公开
标题翻译：通过IL-13受体ALPHA2的靶向治疗癌症
公开(公告)号：US20110268749A1
公开(公告)日：2011-11-03
申请号：US12671652
申请日：2008-07-31
申请人： Warren Strober , Jay A. Berzofsky , Stefan Fichtner-Feigl , Atsushi Kitani , Ivan J. Fuss , Masaki Terabe , Peter Mannon
发明人： Warren Strober , Jay A. Berzofsky , Stefan Fichtner-Feigl , Atsushi Kitani , Ivan J. Fuss , Masaki Terabe , Peter Mannon
IPC分类号： A61K39/395 , A61K31/7088 , A61P35/00 , A61K38/17
CPC分类号： A61K31/00 , A61K38/1793 , A61K2039/505 , C07K16/241 , C12N15/1138 , C12N2310/13 , C12N2310/14
摘要： Disclosed herein are compositions and methods for treating or preventing cancer involving the use of a TNF-alpha antagonist, an IL-13Rα2 antagonist, and/or a AP-I antagonist.
摘要翻译：本文公开了用于治疗或预防涉及TNF-α拮抗剂，IL-13Rα2拮抗剂和/或AP-1拮抗剂的使用的组合物和方法。

4. 发明申请

US20120088244A1 COMPOSITION AND METHODS FOR RAPID DETECTION OF HIV BY LOOP-MEDIATED ISOTHERMAL AMPLIFICATION (LAMP) 有权
标题翻译：通过循环介导的同功酶（LAMP）快速检测HIV的组合物和方法
公开(公告)号：US20120088244A1
公开(公告)日：2012-04-12
申请号：US12918536
申请日：2009-02-25
申请人： S. Michele Owen , Kelly Curtis , Donna Rudolph
发明人： S. Michele Owen , Kelly Curtis , Donna Rudolph
IPC分类号： C12Q1/68 , C07H21/00
CPC分类号： C12Q1/703 , C12Q2531/119
摘要： Methods and compositions for detection of HIV nucleic acids in a sample, such as a biological sample obtained from a human subject, are provided according to embodiments of the present invention which include providing a reaction mixture including at least one LAMP, accelerated LAMP, RT-LAMP or RT-accelerated LAMP assay primer set specific for HIV-I or HIV-2 nucleic acids and the biological sample to be tested for presence of HIV-I and/or HIV-2 nucleic acids; incubating the reaction mixture under conditions suitable to produce a LAMP assay reaction product; and detecting the reaction product. Primers and primer sets for use in LAMP assays of HIV-I or HIV-2 nucleic acids are provided.
摘要翻译：根据本发明的实施方案提供了用于检测样品中的HIV核酸的方法和组合物，例如从人受试者获得的生物样品，其包括提供包含至少一种LAMP，加速LAMP，RT- 针对HIV-1或HIV-2核酸特异性的LAMP或RT加速LAMP测定引物组和待测HIV-1和/或HIV-2核酸存在的生物样品; 在适于产生LAMP测定反应产物的条件下孵育反应混合物; 并检测反应产物。提供了用于HIV-1或HIV-2核酸的LAMP测定中的引物和引物组。

5. 发明申请

US20110086416A1 IMMUNOTOXIN FUSION PROTEINS AND MEANS FOR EXPRESSION THEREOF 有权
标题翻译：免疫蛋白融合蛋白及其表达手段
公开(公告)号：US20110086416A1
公开(公告)日：2011-04-14
申请号：US12718673
申请日：2010-03-05
申请人： David M. Neville, Jr. , Jerry Todd Thompson , Huaizhong Hu , Jung-Hee Woo , Shenglin Ma , Jonathan Mark Hexham , Mary Ellen Digan
发明人： David M. Neville, Jr. , Jerry Todd Thompson , Huaizhong Hu , Jung-Hee Woo , Shenglin Ma , Jonathan Mark Hexham , Mary Ellen Digan
IPC分类号： C12N1/21 , C07H21/04 , C12N15/63
CPC分类号： C07K19/00 , A61K47/6829 , A61K47/6849 , C07K5/1008 , C07K7/06 , C07K7/08 , C07K14/34 , C07K16/2809 , C07K2317/24 , C07K2317/622 , C07K2319/00
摘要： The present invention described and shown in the specification and drawings provides novel recombinant DT-based immunotoxins, and, more specifically anti-T cell immunotoxin fusion proteins. Also provided are immunotoxins that can be expressed in bacterial, yeast, or mammalian cells. The invention also provides means for expression of the immunotoxin fusion protein. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.
摘要翻译：在说明书和附图中描述和示出的本发明提供了新的重组DT-基免疫毒素，更具体地，提供了抗T细胞免疫毒素融合蛋白。还提供了可以在细菌，酵母或哺乳动物细胞中表达的免疫毒素。本发明还提供了表达免疫毒素融合蛋白的方法。要强调的是，该摘要被提供以符合要求抽象的规则，允许搜索者或其他读者快速确定技术公开内容的主题。提交它的理解是，它不会用于解释或限制权利要求的范围或含义。

6. 发明申请

US20100099201A1 METHODS AND COMPOSITIONS RELATING TO ISOCYANATE CONJUGATES 有权
标题翻译：关于异氰酸酯共聚物的方法和组合物
公开(公告)号：US20100099201A1
公开(公告)日：2010-04-22
申请号：US12577241
申请日：2009-10-12
申请人： Paul D. Siegel , Tinashe Blessing Ruwona , Donald H. Beezhold , Victor Johnson , Detlef Schmechel
发明人： Paul D. Siegel , Tinashe Blessing Ruwona , Donald H. Beezhold , Victor Johnson , Detlef Schmechel
IPC分类号： G01N33/53 , C07K16/00
CPC分类号： C07K16/44 , G01N33/5308
摘要： Compositions are provided according to embodiments of the present invention which include an isolated antibody or antigen binding antibody fragment characterized by binding specificity for a conjugate which is a reaction product of a protein moiety and an isocyanate moiety. Methods of detecting diisocyanate-protein conjugates in a sample are provided according to embodiments of the present invention which include contacting a sample with one or more isolated antibodies or antigen binding antibody fragments characterized by binding specificity for corresponding diisocyanate-protein conjugate antigens.
摘要翻译：根据本发明的实施方案提供组合物，其包括分离的抗体或抗原结合抗体片段，其特征在于对于作为蛋白质部分和异氰酸酯部分的反应产物的缀合物的结合特异性。根据本发明的实施方案提供检测样品中二异氰酸酯 - 蛋白质缀合物的方法，其包括使样品与一种或多种分离的抗体或抗原结合抗体片段接触，其特征在于相应的二异氰酸酯 - 蛋白质缀合物抗原的结合特异性。

7. 发明申请

US20120122123A1 DETECTION OF ANTHRAX PATHOGENICITY FACTORS 有权
标题翻译：检测ANTHRAX致病因子
公开(公告)号：US20120122123A1
公开(公告)日：2012-05-17
申请号：US11675233
申请日：2007-02-15
申请人： ANNE E. BOYER , Conrad P. Quinn , John R. Barr
发明人： ANNE E. BOYER , Conrad P. Quinn , John R. Barr
IPC分类号： G01N33/566 , G01N21/64 , C12M1/34
CPC分类号： G01N33/56911 , G01N2333/32 , G01N2500/00
摘要： One major problem in diagnosis methods presently available for anthrax is that these methods require several days to produce a result. The only existing treatment for anthrax requires administration soon after infection at a time when patients are exhibiting only mild flu-like symptoms. Thus, a patient may be days beyond the time when treatment would be effective by the time a diagnosis is made. The present invention reduces diagnosis time to as little as four hours providing same day identification of anthrax radically increasing the odds of delivering proper treatment and patient recovery. The rapid identification of anthrax lethal factor activity exhibited by the instant invention is also amenable to in vivo screening protocols for the discovery and development of anthrax vaccines and lethal factor inhibitors. The instant invention isolates and concentrates lethal factor and lethal toxin from nearly any biological sample. By capitalizing on the endopeptidase activity of lethal factor the present invention amplifies output signals producing reliable detection of picomolar concentrations of lethal factor. The instant invention involves novel purification and detection techniques and substrates for rapid, reproducible, and quantitative measurements of anthrax lethal factor in biological samples.
摘要翻译：目前可用于炭疽的诊断方法的一个主要问题是这些方法需要几天才能产生结果。炭疽病唯一现有的治疗方法需要在感染后立即进行治疗，当时患者只出现轻微的流感样症状。因此，患者可能是在诊断时治疗有效的时间。本发明将诊断时间缩短至少于4小时，同时提供炭疽的同一天鉴定，从而大大增加了提供适当治疗和患者恢复的几率。本发明显示的炭疽致死因子活性的快速鉴定也适用于发现和发展炭疽疫苗和致死因子抑制剂的体内筛选方案。本发明从几乎任何生物样品中分离和浓缩致死因子和致死毒素。通过利用致死因子的内肽酶活性，本发明扩增了产生对皮摩尔浓度致死因子的可靠检测的输出信号。本发明涉及用于生物样品中炭疽致死因子的快速，可重复和定量测量的新颖的纯化和检测技术和底物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式